X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6) 6
index medicus (6) 6
aged (5) 5
male (5) 5
middle aged (5) 5
multiple myeloma (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
care and treatment (4) 4
female (4) 4
stem cell transplantation (4) 4
transplantation (4) 4
adult (3) 3
aged, 80 and over (3) 3
clinical trials (3) 3
disease-free survival (3) 3
double-blind method (3) 3
hematology, oncology and palliative medicine (3) 3
kaplan-meier estimate (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
multiple myeloma - mortality (3) 3
multiple myeloma - therapy (3) 3
administration, oral (2) 2
bortezomib (2) 2
cancer and oncology (2) 2
cancer och onkologi (2) 2
clinical medicine (2) 2
combination therapy (2) 2
dexamethasone (2) 2
dexamethasone - administration & dosage (2) 2
diseases (2) 2
drug dosages (2) 2
drug therapy (2) 2
hematology (2) 2
hemic and lymphatic diseases (2) 2
immune system diseases (2) 2
infusions, intravenous (2) 2
klinisk medicin (2) 2
multiple myeloma - complications (2) 2
multiple myeloma - diagnosis (2) 2
multiple myeloma - drug therapy (2) 2
multiple myeloma - pathology (2) 2
oncology (2) 2
patients (2) 2
proportional hazards models (2) 2
quality of life (2) 2
quality-of-life (2) 2
relapse (2) 2
remission induction (2) 2
survival (2) 2
transplantation, autologous (2) 2
transplantation, homologous (2) 2
treatment outcome (2) 2
abridged index medicus (1) 1
alleles (1) 1
allogeneic transplantation (1) 1
amyloidosis - complications (1) 1
amyloidosis - diagnosis (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antitumor-activity (1) 1
article (1) 1
autografts (1) 1
autologous transplantation (1) 1
biopsy (1) 1
bisphosphonates (1) 1
bone density conservation agents - administration & dosage (1) 1
bone density conservation agents - adverse effects (1) 1
bone diseases - diagnostic imaging (1) 1
bone diseases - etiology (1) 1
bone diseases - mortality (1) 1
bone diseases - prevention & control (1) 1
bone marrow (1) 1
bone marrow transplantation - methods (1) 1
bone-resorption (1) 1
boron compounds (1) 1
boron compounds - administration & dosage (1) 1
boron compounds - adverse effects (1) 1
boronic acids - administration & dosage (1) 1
bortezomib-thalidomide-dexamethasone (1) 1
carfilzomib (1) 1
carpal tunnel syndrome - complications (1) 1
carpal tunnel syndrome - diagnosis (1) 1
cd3 complex (1) 1
chemotherapy (1) 1
clodronate (1) 1
conferences and conventions (1) 1
diphosphonates - administration & dosage (1) 1
diphosphonates - adverse effects (1) 1
dkk1 (1) 1
dosage and administration (1) 1
dose-response relationship, drug (1) 1
drug administration schedule (1) 1
edema - complications (1) 1
edema - diagnosis (1) 1
efficacy (1) 1
exanthema (1) 1
exanthema - chemically induced (1) 1
fatal outcome (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 973 - 982
Summary Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma.... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BISPHOSPHONATES | MULTICENTER | EFFICACY | ONCOLOGY | CLODRONATE | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | DKK1 | CHEMOTHERAPY | BONE-RESORPTION | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Jaw Diseases - chemically induced | Stem Cell Transplantation | Bone Diseases - etiology | Multiple Myeloma - therapy | Time Factors | Aged, 80 and over | Female | Diphosphonates - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Multiple Myeloma - diagnosis | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Bone Diseases - prevention & control | Treatment Outcome | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Bone Diseases - diagnostic imaging | Scandinavian and Nordic Countries | Radiography | Bone Diseases - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Aged | Infusions, Intravenous | Osteonecrosis - chemically induced | Medicine, Experimental | Clinical trials | Medical research | Care and treatment | Multiple myeloma | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 12, pp. 2039 - 2051
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 02/2003, Volume 44, Issue 2, p. 177
Changes in the amount and distribution of amyloid lesions have been difficult to monitor because they can usually be demonstrated only by evident symptoms or... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.